- India restrict Pakistan to 105-8 in Women's T20 World Cup
- England target repeat of Pakistan Test whitewash
- Penrith Panthers win fourth straight NRL title after downing Storm
- Weary Sinner happy for day off after battling into Shanghai last 16
- Pakistan's Masood warns England still a force without Stokes
- Madrid's Carvajal to miss several months after serious knee injury
- Israel pounds Lebanon ahead of Hamas attack anniversary
- Two elephants die in flash flooding in northern Thailand
- Sabalenka targets world number one and Wuhan hat-trick
- Toddler among 4 dead in migrant Channel crossings
- Tunisia votes with Saied set for re-election
- Bagnaia sets 'example' with Japan MotoGP win to cut gap on Martin
- Intense Israeli bombing rocks Beirut ahead of war anniversary
- Mozambique vote: no suspense but some disillusion
- Austrian rapper channels anti-racist rage in Romani hip-hop songs
- Ohtani magic powers Dodgers over Padres in MLB playoff thriller
- Five of the best: Pakistan-England Test thrillers
- Man sets arm on fire as marches across US mark Gaza war anniversary
- Vietnam's young coffee entrepreneurs brew up a revolution
- Trump rallies at site of failed assassination: 'Never quit'
- Too hot by day, Dubai's floodlit beaches are packed at night
- Is music finally reckoning with #MeToo?
- Fans hail Trump's 'guts' as he returns to site of rally shooting
- Lebanon state media says 'very violent' Israeli strikes hit south Beirut
- Guardians maul Tigers, miracle Mets rally in MLB series openers
- Lebanon state media says Israeli strikes hit south Beirut
- Miami on track for MLS record points after win in Toronto
- Madrid beat Villarreal but Carvajal suffers knee injury
- Madrid beat Villarreal to move level with Liga leaders Barcelona
- Monaco take top spot in Ligue 1 with win at Rennes
- French rugby player on rape charge whistled but 'serene' on return
- Madrid beat Villarreal to level Liga leaders Barca
- Thuram treble fires Inter past Torino and up to second
- 'Fight': defiant Trump jets in to site of rally shooting
- Toddler among 3 dead in migrant Channel crossings
- Mexico City's new mayor sworn in with pledges on water, housing
- Israel on alert ahead of Hamas attack anniversary
- Guardians maul Tigers in MLB playoff series opener
- Macron criticises Israel on Gaza, Lebanon operations
- French rugby player whistled but 'serene' on return amid ongoing rape case
- Kovacic stars as Man City sink Fulham to get title bid back on track
- Retegui hat-trick fires five-star Atalanta to hammering of Genoa
- Heavyweights Australia, England off to World Cup winning starts
- Visiting UN refugee agency chief decries 'terrible crisis' in Lebanon
- Spinners come to party as England defeat Bangladesh at T20 World Cup
- Search continues for missing in deadly Bosnia floods
- Man City sink Fulham to get title bid back on track
- France's Auradou whistled on Pau return in Perpignan loss amid ongoing rape case
- A 'forgotten' valley in storm-hit North Carolina, desperate for help
- Arsenal hit back in style after Southampton scare
Weight loss drug safe, effective for under-12 kids: study
A weight loss drug has been found to be broadly safe and effective for children under 12 with obesity, according to a small study on Wednesday that was cautiously welcomed by outside experts.
A new class of weight loss drugs called GLP-1 agonists have become hugely popular across the world in the last couple of years, sparking stock shortages and widespread off-label use despite steep prices.
But little research has been conducted on how these new drugs work on young children.
Obesity in children and adolescents has quadrupled since 1990, according to the World Health Organization. Yet there are no regularly prescribed drugs which treat obesity in children.
The study looked at an older GLP-1 agonist called liraglutide, sold under the brand name Saxenda by Danish pharmaceutical giant Novo Nordisk, which also makes the blockbuster semaglutide drugs Ozempic and Wegovy.
The US-based phase 3 trial, which was funded by Novo Nordisk, was the first to investigate liraglutide's effect on under 12s.
It involved 82 children aged six to 12 with obesity, some of whom were randomly assigned a daily injection of liraglutide, while others received a placebo. The children were also encouraged to exercise and eat healthily.
After a little over a year, 46 percent of the children receiving the drug saw their body mass index (BMI) shrink by at least five percent, according to the study.
Only nine percent of the placebo group had such a reduction in BMI, which also takes into account height and was used because children at these ages grow quickly.
Some children taking the drug also reported side effects such as vomiting and nausea, which was in line with those experienced by adults, the researchers said.
Lead study author Claudia Fox of the University of Minnesota said that kids living with obesity are currently told to just "try harder with diet and exercise".
But these findings raise hopes that a drug could one day help these children "live healthier, more productive lives," she said in a statement.
- Stunted growth fear -
Stephen Burgess, a statistician at the University of Cambridge not involved in the research, said the study showed that drugs could "help change the trajectory of weight gain in young children".
"While receiving weight loss injections is clearly not the ideal solution to childhood obesity, reductions in body mass index for trial participants were sustained even beyond the duration of the treatment course," he told AFP.
Simon Cork, a researcher at the UK's Anglia Ruskin University, said that "the evidence that liraglutide is both safe and effective in children is positive".
But one concern about children taking weight loss drugs such as GLP-1 agonists which work by suppressing appetite is that this could risk stunting growth, he warned.
The new study showed no evidence this had occurred.
But Cork said that "further studies over longer time periods will need to be undertaken to ensure that appetite suppression in these children does not have unforeseen negative consequences later in their development".
The study was presented at the European Association for the Study of Diabetes being held in Madrid, and was also published in the New England Journal of Medicine.
M.Fischer--AMWN